Drug Trial Radar · NCT05261399
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
341
Actual
Start
Aug 3, 2022
Primary completion
Jul 6, 2026
Study completion Nov 23, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Mar 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib.
Conditions
- Carcinoma
- Non-Small-Cell Lung
Interventions
SavolitinibDrug
300 mg savolitinib (3 × 100 mg tablets twice daily) Administrative route : oral
OsimertinibDrug
80 mg osimertinib (1 × 80 mg tablet once daily) Administrative route : oral
PemetrexedDrug
Pemetrexed (500 mg/m2) Administrative route : IV infusion
CisplatinDrug
Cisplatin (75 mg/m2) Administrative route : IV infusion
CarboplatinDrug
Carboplatin (AUC5) Administrative route : IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on osimertinib.Time frame: Approximately 36.5 months post first subject randomized
Locations
214 sites in 27 countries. Site status is shown where the registry gives one.
Research Site
Orlando, Florida
Research Site
Honolulu, Hawaii
Research Site
New Brunswick, New Jersey
Research Site
New York, New York
Research Site
Nashville, Tennessee
Research Site
Buenos Aires, Argentina
Research Site
CABA, Argentina
Research Site
Florida, Argentina
Research Site
La Rioja, Argentina
Research Site
Rosario, Argentina
Research Site
Rosario, Argentina
Research Site
San Miguel de Tucumán, Argentina
Research Site
Viedma, Argentina
Research Site
Fremantle, Australia
Research Site
Southport, Australia
Research Site
Waratah NSW, Australia
Research Site
Westmead, Australia
Research Site
Brussels, Belgium
Research Site
Ghent, Belgium
Research Site
Roeselare, Belgium
Research Site
Belo Horizonte, Brazil
Research Site
Cachoeiro de Itapemirim, Brazil
Research Site
Ijuí, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Salvador, Brazil
Research Site
Salvador, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
Vitória, Brazil
Research Site
Toronto, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Santiago, Chile
Research Site
Baoding, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Bengbu, China
Showing 40 of 214 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.